Asset-generation through our game-changing antibody platform

      We are driven by curiosity and innovation to develop a solid portfolio based on asset-generation through our game-changing antibody platform, AbiProt®. Our approach is different: we start with patients and their needs for new medicines, with a goal to generate novel medicines against disease-modifying human protein target.

      We are committed to finding treatments for severe diseases with large unmet clinical needs such as pain using our unique angle of a targeted functionality antibody approach.

      Oblique Therapeutics:

      • is a curiosity-driven, innovative biotech company with strong scientific acumen and drive for increasing the bandwidth of antibody therapeutics, mainly focusing on pain
      • is agnostic when it comes to targets and indications using AbiProt® in collaborative work with a partner
      • has a vision to be a global industry leader focused on transformative antibody medicines